Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) reported that stockholders approved all five proposals at the May 22, 2026 Annual Meeting, which was adjourned to June 8, 2026.
Founder, president & CEO Lisa Conte will present virtually at the Emerging Growth Conference on June 10, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – JAGX
In the Jun 9 session, JAGX gained 3.30%, reflecting a moderate positive market reaction. Argus tracked a peak move of +12.4% during that session. Argus tracked a trough of -4.1% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 28 | Clinical program update | Positive | +3.1% | Ethnobotanical research and data supporting crofelemer for rare GI disorders. |
| May 27 | Nasdaq compliance & growth | Positive | +2.6% | Regained Nasdaq bid-price compliance and highlighted strong revenue growth. |
| May 20 | Q1 2026 earnings | Positive | -5.5% | Strong revenue and operating turnaround but shares fell after results. |
| May 20 | Investor webcast notice | Neutral | +2.8% | Announcement of webcast and conference presentation on Q1 results and updates. |
| May 19 | Clinical trial progress | Positive | -9.3% | MVID pivotal trial moved into active-treatment extension to support NDA. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has produced mixed reactions: three events with positive or neutral sentiment aligned with gains, while two fundamentally positive updates (earnings and clinical progress) coincided with sell-offs.
Over the past few months, Jaguar reported a sharp Q1 2026 turnaround with total net revenue rising to $20.3 million and highlighted major license deals and pivotal crofelemer development for rare intestinal failure. The company regained Nasdaq bid-price compliance and advanced its MVID trial into an active-treatment extension phase targeting an NDA around mid‑2027. Ethnobotanical research and additional clinical data further underscored the crofelemer franchise. Today’s approval of all annual meeting proposals fits into this series of corporate and clinical milestones, but contrasts with the current share price weakness.
Key Terms
schedule 14a regulatory
proxy statement regulatory
securities and exchange commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register
SAN FRANCISCO, CA / ACCESS Newswire / June 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's May 22, 2026 Annual Meeting of Stockholders (the "Annual Meeting"), which was adjourned until June 8, 2026.
Five proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on April 30, 2026 and supplemental information filed with the SEC. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website.
Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference
When: Wednesday, June 10, 2026 from 12:35 - 1:05 PM Eastern
Where: Online (Click Here)
Registration link for conference: Click Here
Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the June 2026 Emerging Growth Conference. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire